Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem)

NCT ID: NCT03007576

Last Updated: 2019-11-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-08-01
• Study Completion Date: 2019-08-31

Brief Summary

Osteoarthritis (OA) is a common and incurable disease for the elderly in Taiwan, so it is an important mission to develop a new treatment for OA. Recently, cellular therapy is a new and popular medical treatment around the world, one of them is "Mesenchymal Stromal Cells (MSCs)". MSCs are found in many tissues of human body and play an important role for repairing, regeneration, anti-inflammatory and chondrogenesis. So, MSC product, RegStem, for osteoarthritis treatment becomes a developing target for new generation drugs.

This study is to isolate and expand MSCs(RegStem) from infrapatellar fat pad of subject. When the number of MSCs expands to 1×10^8, cell will be cryopreserved in the liquid nitrogen tank until all release tests passed. On the distribution day, cell will be thawed and injected into joint cavity of patient (5×10^7). Subjects will be monitored after MSC product infusion of seven days, one month, six months and one year. The monitoring items include the changes of knee (by appearance, X-ray and MRI of knee) and pain improvement (by questionnaire).

Conditions

Osteoarthritis,Knee

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

RegStem

Autologous MSC, 5×10\^7 cells, one injection

Group Type: EXPERIMENTAL

RegStem

Intervention Type: BIOLOGICAL

RegStem, 1.5 ml, one injection

Interventions

RegStem

RegStem, 1.5 ml, one injection

Intervention Type: BIOLOGICAL

Other Intervention Names

MSC

Eligibility Criteria

Inclusion Criteria

1. Subjects who understand and sign the informed consent form for this study

2. Grade 2~3 osteoarthritis according to the Kellgren-Lawrence grading scale with one-month X-ray

3. Age is 50~75 years old

4. Postmenopausal women

5. VAS scores in 50 to 90 mm

Exclusion Criteria

1. Abnormal of liver and kidney: GOT and GPT > 100 IU/L, BUN >22 mg/dl and creatinine > 1.2 mg/dl.

2. Positive serology for HIV, HTLV-1/2 and syphilis

3. Women who are pregnant or breast feeding

4. Serious pre-existing medical conditions: coagulation disorders, cardiovascular diseases (arrhythmias, myocardial infarction and surgery), renal diseases (chronic renal failure), liver diseases (cirrhosis), diabetes mellitus type I, cancer history.

5. Other joint diseases: knee deformity (knee varus greater than 10 degree or valgus greater than 20 degree), rheumatic arthritis, gouty arthritis, septic arthritis, serious meniscal tear, other autoimmune arthritis.

6. Skin inflammatory of knee

7. Knee pain caused by referred pain from spine disease or hip joint disease. Knee pain combined with pain from spine disease or hip disease.

8. Immunosuppressive state

9. Subjects who were injected with hyaluronic acid and PRP in the past 6 months

10. Body mass index (BMI) greater than 30

11. Have a history of allergic reaction of any medication

12. Participation in another clinical trial or treatment within 3 months

13. Other pathologic conditions or circumstances that difficult participation in this study according to PI's evaluations

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Far Eastern Memorial Hospital

OTHER

Sponsor Role: collaborator

EMO Biomedicine Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Far Eastern Memorial Hospital

Taipei, , Taiwan

Countries

Taiwan

Other Identifiers

EMOCT01

Identifier Type: -

Identifier Source: org_study_id